tiprankstipranks
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

YMAB Stock Latest News

Y-Mabs Therapeutics: Promising Pipeline and Positive Financial Outlook Justify Buy Rating
RatingsY-Mabs Therapeutics: Promising Pipeline and Positive Financial Outlook Justify Buy Rating
26d ago
YMAB
Y-mAbs Therapeutics price target lowered to $12 from $22 at H.C. Wainwright
PremiumThe Fly
Y-mAbs Therapeutics price target lowered to $12 from $22 at H.C. Wainwright
26d ago
YMAB
Positive Outlook on Y-Mabs Therapeutics Despite Adjusted Price Target, Driven by Promising Radiopharmaceutical Platform
PremiumRatings
Positive Outlook on Y-Mabs Therapeutics Despite Adjusted Price Target, Driven by Promising Radiopharmaceutical Platform
1M ago
YMAB
Y-mAbs Therapeutics price target lowered to $12 from $14 at BofA
PremiumThe Fly
Y-mAbs Therapeutics price target lowered to $12 from $14 at BofA
1M ago
YMAB
Y-mAbs Therapeutics price target lowered to $18 from $21 at Truist
PremiumThe Fly
Y-mAbs Therapeutics price target lowered to $18 from $21 at Truist
1M ago
YMAB
Y-mAbs Therapeutics price target lowered to $7 from $11 at Morgan Stanley
PremiumThe FlyY-mAbs Therapeutics price target lowered to $7 from $11 at Morgan Stanley
1M ago
YMAB
Y-mAbs Therapeutics price target lowered to $21 from $23 at Oppenheimer
Premium
The Fly
Y-mAbs Therapeutics price target lowered to $21 from $23 at Oppenheimer
1M ago
YMAB
Positive Growth Prospects and Strategic Developments Drive Buy Rating for Y-Mabs Therapeutics
Premium
Ratings
Positive Growth Prospects and Strategic Developments Drive Buy Rating for Y-Mabs Therapeutics
1M ago
YMAB
Y-mAbs Therapeutics Reports 2024 Financial Results
PremiumCompany Announcements
Y-mAbs Therapeutics Reports 2024 Financial Results
1M ago
YMAB
Y-mAbs Therapeutics’ Earnings Call Highlights Mixed Results
PremiumCompany Announcements
Y-mAbs Therapeutics’ Earnings Call Highlights Mixed Results
1M ago
YMAB
Morning Movers: Target, Best Buy slipping after earnings as tariffs take effect
PremiumThe Fly
Morning Movers: Target, Best Buy slipping after earnings as tariffs take effect
1M ago
SE
AZO
Y-mAbs Therapeutics reports Q4 EPS (15c), consensus (13c)
PremiumThe Fly
Y-mAbs Therapeutics reports Q4 EPS (15c), consensus (13c)
1M ago
YMAB
Y-mAbs Therapeutics sees 2025 revenue $75M-$90M, consensus $105.76M
PremiumThe FlyY-mAbs Therapeutics sees 2025 revenue $75M-$90M, consensus $105.76M
1M ago
YMAB
Y-mAbs announces publication of Phase 2 interim results on naxitamab
Premium
The Fly
Y-mAbs announces publication of Phase 2 interim results on naxitamab
1M ago
YMAB
YMAB Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
YMAB Earnings this Week: How Will it Perform?
2M ago
YMAB
Y-mAbs Therapeutics presents translational pharmacokinetics data of GD2-SADA
PremiumThe Fly
Y-mAbs Therapeutics presents translational pharmacokinetics data of GD2-SADA
2M ago
YMAB
Y-mAbs Therapeutics Updates on Business and Clinical Trials
PremiumCompany Announcements
Y-mAbs Therapeutics Updates on Business and Clinical Trials
3M ago
8K
YMAB
Y-mAbs Therapeutics Announces Strategic Business Realignment
PremiumCompany Announcements
Y-mAbs Therapeutics Announces Strategic Business Realignment
3M ago
8K
YMAB
Y-mAbs Therapeutics appoints Gentilcore as SVP, head of DANYELZA unit
PremiumThe Fly
Y-mAbs Therapeutics appoints Gentilcore as SVP, head of DANYELZA unit
3M ago
YMAB
Y-mAbs Therapeutics announces milestones for 2025
PremiumThe FlyY-mAbs Therapeutics announces milestones for 2025
3M ago
YMAB
Y-mAbs Therapeutics reports preliminary FY24 revenue $88M, consensus $88.53M
Premium
The Fly
Y-mAbs Therapeutics reports preliminary FY24 revenue $88M, consensus $88.53M
3M ago
YMAB
Y-mAbs Therapeutics price target lowered to $14 from $17 at BofA
Premium
The Fly
Y-mAbs Therapeutics price target lowered to $14 from $17 at BofA
3M ago
YMAB

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >